Reviv3 Procare Company (RVIV) Q2 2026 Earnings Report

Reviv3 Procare Company reported a positive QQ2 2026 bottom line, underpinned by solid gross and operating profitability despite revenue not being disclosed in the provided data. Gross profit was 5.54 million for the quarter, contributing to an operating income of 0.90 million and a net income of 0.705 million, translating to an EPS of 0.10 (diluted 0.09). Year-over-year, net income rose roughly 136%, and gross profit advanced about 34% YoY, signaling meaningful cost discipline and favorable product mix momentum even as top-line visibility remains opaque. The company ended the quarter with a robust cash position (approximately 4.98 million) and a net cash balance of about -4.47 million in net debt, highlighting liquidity and financial flexibility to fund growth initiatives or navigate near-term uncertainties.

Despite the absence of revenue disclosure in the quarter, the earnings mix suggests disciplined SG&A management (SG&A and related expenses totaling roughly 4.63 million) and a favorable EBITDA outcome of 0.90 million. The balance sheet remains solid, with total assets of 16.24 million, total stockholders’ equity of 11.08 million, and only modest liabilities (total liabilities 0.58 million). The company’s liquidity position and net cash posture provide a cushion for potential investments in international expansion, product innovation, and distribution channel optimization. Investors should monitor revenue trajectory and cadence as visibility improves, as well as any margin expansion opportunities tied to scale and mix shifts.